 YONKERS, N.Y., Dec. 13, 2022 GLOBE NEWSWIRE ContraFect Corporation Nasdaq: CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a securities purchase agreement with ... The post ContraFect Announces Pricing of 7.0 Million Registered Direct Offering and... 